Treating Metastatic Non-Small Cell Lung Cancer With Driver Mutations

What’s the best approach for treating metastatic non-small cell lung cancers that possess certain mutations? In this episode of The Fellow on Call: The Heme/Onc Podcast, the group endeavors to answer that very question. To treat driver mutations, molecular testing is needed to identify the driver gene, and from there, targeted therapy options are available. The Fellow on Call notes to pay attention to the specific types of mutations in the EGFR, and lists a first-line standard of care treatment for patients with EGFR, with data to back it. They also discuss how to approach ALK, and other mutations.